Evidence map›Paper›PMID 35163475›Full record

ReviewInternational journal of molecular sciences2022

Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via

Yasunari Matsuzaka, Yukihiko Hirai, Kazuo Hashido, Takashi Okada

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Extracellular Vesicles: A New Star for Gene Drug Delivery.International journal of nanomedicine · 2024
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yasunari MatsuzakaDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Yukihiko HiraiDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.
Kazuo HashidoAdministrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan.
Takashi OkadaDivision of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.ORCID 0000-0002-2910-3797
Tokyo University of Science · JPNational Center of Neurology and Psychiatry · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is caused by loss-of-function mutations in the dystrophin gene on chromosome Xp21. Disruption of the dystrophin-glycoprotein complex (DGC) on the cell membrane causes cytosolic Ca

Indexed as

AnimalsCell-Free Nucleic AcidsDependovirusExtracellular VesiclesGenetic TherapyGenetic VectorsHumansMuscular Dystrophy, DuchenneSatellite Cells, Skeletal MuscleSphingomyelin PhosphodiesteraseTransduction, GeneticCell-Free Nucleic AcidsSMPD3 protein, humanSphingomyelin Phosphodiesteraseadeno-associated virusDuchenne muscular dystrophyextracellular vesicleextracellular vesicle-capsulated adeno-associated virus vectormicroRNAsmyofiber degenerationnSMase2/Smpd3satellite cell

Identifiers

PMID35163475
PMCPMC8836108
OpenAlexW4210554361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.